News
FOLD
--
0.00%
--
Amicus Therapeutics receives PRIME designation for CLN6 batten disease gene therapy
Amicus Therapeutics (FOLD) announced that the European Medicines Agency has granted priority medicines designation to AT-GTX-501, the Company’s investigational gene therapy for children living with variant late infantile neuronal ceroid lipofuscinosis
Seekingalpha · 3d ago
Amicus gene therapy nabs accelerated review in Europe for batten disease
Amicus Therapeutics (FOLD) announced that the European Medicines Agency has granted priority medicines designation to AT-GTX-501, the Company’s investigational gene therapy for children living with variant late infantile neuronal ceroid lipofuscinosis
Seekingalpha · 3d ago
Fintech Focus For September 24, 2020
Benzinga · 3d ago
Taysha Gene Therapies Seeks $125 Million IPO For Ambitious Pipeline
Taysha Gene Therapies has filed proposed terms for a $125 million IPO.The firm is developing gene therapies for various neurodegenerative and other monogenic disease candidates.TSHA is still at a preclinical stage of development for its entire pipeline and the IPO isn't cheap, so may be more suited to long-term hold institutional investors.
Seekingalpha · 09/17 19:17
Is Amicus Therapeutics, Inc. (FOLD) Going to Burn These Hedge Funds?
The latest 13F reporting period has come and gone, and Insider Monkey have plowed through 823 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F filings show the funds' and investors' portfolio positions as of June 30th, when the S&P 500 Index
Insider Monkey · 09/15 13:07
Amicus Therapeutics (FOLD) Down 7.5% Since Last Earnings Report: Can It Rebound?
Amicus Therapeutics (FOLD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks · 09/09 16:30
How Does Amicus Therapeutics' (NASDAQ:FOLD) CEO Pay Compare With Company Performance?
John Crowley has been the CEO of Amicus Therapeutics, Inc. (NASDAQ:FOLD) since 2011, and this article will examine the...
Simply Wall St. · 09/04 11:37
Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2020
CRANBURY, N.J., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that members of the Amicus senior leadership team will participate in upcoming presentations at the following virtual investor conferences in September: * Citi’s 15th Annual BioPharma Virtual Conference on Thursday, September 10, 2020 at 8:55 a.m. E.T. * Cantor Virtual Global Healthcare Conference on Wednesday, September 16, 2020 at 10:00 a.m. E.T. * Bank of America Global Healthcare Conference on Friday, September 18, 2020 at 4:45 p.m. B.S.T. (11:45 a.m. E.T.)A live audio webcast of each presentation can be accessed via the Investors section of the Amicus Therapeutics corporate website at https://ir.amicusrx.com/events-and-presentations.About Amicus Therapeutics Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare metabolic diseases. With extraordinary patient focus, Amicus Therapeutics is committed to advancing and expanding a robust pipeline of cutting-edge, first- or best-in-class medicines for rare metabolic diseases. For more information please visit the company’s website at www.amicusrx.com, and follow on Twitter and LinkedIn.CONTACT: Investors: Amicus Therapeutics Andrew Faughnan Director, Investor Relations afaughnan@amicusrx.com (609) 662-3809Media: Amicus Therapeutics Diana Moore Head of Global Corporate Communications dmoore@amicusrx.com (609) 662-5079FOLD–G
GlobeNewswire · 09/03 12:00
Citigroup Maintains Buy on Amicus Therapeutics, Raises Price Target to $20
Citigroup maintains Amicus Therapeutics (NASDAQ:FOLD) with a Buy and raises the price target from $15 to $20.
Benzinga · 08/11 11:26
Amicus Therapeutics Affirms FY2020 Sales Guidance from $250.00M-260.00M to $250.00M-260.00M
Amicus Therapeutics (NASDAQ:FOLD) affirms FY2020 sales outlook from $250.00 million-260.00 million to $250.00 million-260.00 million.
Benzinga · 08/10 13:16
Amicus Therapeutics (FOLD) Reports Q2 Loss, Misses Revenue Estimates
Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of 23.08% and -0.48%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 08/10 12:25
Recap: Amicus Therapeutics Q2 Earnings
Shares of Amicus Therapeutics (NASDAQ:FOLD) rose 0.6% in pre-market trading after the company reported Q2 results.Quarterly Results Earnings per share increased 44.44% year over year to ($0.20), which beat the estimate of ($0.26).Revenue of $62,353,000 rose by
Benzinga · 08/10 11:27
Amicus Therapeutics Q2 EPS $(0.20) Beats $(0.26) Estimate, Sales $62.35M Miss $62.38M Estimate
Amicus Therapeutics (NASDAQ:FOLD) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $(0.26) by 23.08 percent. This is a 44.44 percent increase over losses of $(0.36) per share
Benzinga · 08/10 11:13
Amicus Therapeutics Announces Second Quarter 2020 Financial Results and Corporate Updates
Galafold 2Q2020 Revenue of $62.4 Million, On-Track to Achieve 2020 Revenue Guidance of  $250M-$260MAT-GAA Phase 3 PROPEL Study Readout and Rolling BLA Submission to U.S. FDA on ScheduleAdvancing Industry-Leading Rare Disease Gene Therapy PortfolioPath to Prof
GlobeNewswire · 08/10 11:00
Amicus Therapeutics to Present at the BTIG Virtual Biotechnology Conference
CRANBURY, N.J., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that members of the Amicus senior leadership team will participate in a fireside chat at the BTIG Virtual Biotechnology Conference on Tuesday, August 11, 2020
GlobeNewswire · 08/04 11:00
Will Amicus Therapeutics (FOLD) Report Negative Earnings Next Week? What You Should Know
Amicus Therapeutics (FOLD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks · 08/03 16:31
New Strong Sell Stocks for July 31st
Here are 5 stocks added to the Zacks Rank 5 (Strong Sell) List today.
Zacks · 07/31 11:42
Amicus Therapeutics to Announce Second Quarter 2020 Financial Results on August 10, 2020
CRANBURY, N.J., July 28, 2020 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Monday, August 10, 2020 at 8:30 a.m. ET to discuss financial results for the second quar
GlobeNewswire · 07/28 11:00
Applied DNA's COVID-19 Vaccine, And Other News: The Good, Bad And Ugly Of Biopharma
Seeking Alpha - Article · 07/20 11:34
Amicus Therapeutics secures $400M in debt financing
Amicus Therapeutics (NASDAQ:FOLD) inks an agreement with Hayfin Capital Management for a $400M credit facility at 6.5% above LIBOR subject to a 1% floor. T
seekingalpha · 07/17 17:00
Webull provides a variety of real-time FOLD stock news. You can receive the latest news about Amicus through multiple platforms. This information may help you make smarter investment decisions.
About FOLD
Amicus Therapeutics, Inc. is a biotechnology company focused on discovering, developing and delivering medicines for people living with rare metabolic diseases. The Company is engaged in developing a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio.
More